BiomX (PHGE) Total Non-Current Liabilities (2018 - 2026)
BiomX's (PHGE) quarterly Total Non-Current Liabilities came in at $383000.0 in Q2 2026, down 96.97% year-over-year from $12.6 million in Q2 2025, and down 77.27% quarter-over-quarter from $1.7 million in Q1 2026.
Analysis
BiomX (PHGE) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
BiomX has disclosed Total Non-Current Liabilities across 9 years of filings, most recently posting $383000.0 for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities fell 96.97% year-over-year to $383000.0; the TTM figure through Jun 2026 stood at $383000.0 (down 96.97% YoY), while the FY2025 annual figure was $706000.0, down 93.47% from the prior year.
- Total Non-Current Liabilities came in at $383000.0 for Q2 2026 at BiomX, down from $1.7 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $33.9 million in Q2 2024 to a low of $383000.0 in Q2 2026.
- Average Total Non-Current Liabilities over 5 years is $13.1 million, with a median of $13.1 million recorded in 2024.
- Year-over-year, Total Non-Current Liabilities surged 261.51% in 2022 and slumped 96.97% in 2026.
- Over 5 years, Total Non-Current Liabilities stood at $16.6 million in 2022, then tumbled by 34.92% to $10.8 million in 2023, then increased by 0.43% to $10.8 million in 2024, then sank by 93.47% to $706000.0 in 2025, then tumbled by 45.75% to $383000.0 in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $383000.0 in Q2 2026, $1.7 million in Q1 2026, and $706000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 1.17 Bn |
| 10 | BiomX | 1.55 Mn | 7.73 Mn | 97,000.00 | 383,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 383,000.00 |
| Mar 31, 2026 | 1.69 Mn |
| Dec 31, 2025 | 706,000.00 |
| Sep 30, 2025 | 10.46 Mn |
| Jun 30, 2025 | 12.63 Mn |
| Mar 31, 2025 | 14.13 Mn |
| Dec 31, 2024 | 10.82 Mn |
| Sep 30, 2024 | 13.14 Mn |
| Jun 30, 2024 | 33.89 Mn |
| Dec 31, 2023 | 10.77 Mn |
| Sep 30, 2023 | 12.12 Mn |
| Jun 30, 2023 | 13.72 Mn |
| Mar 31, 2023 | 15.06 Mn |
| Dec 31, 2022 | 16.55 Mn |
| Sep 30, 2022 | 17.86 Mn |
| Jun 30, 2022 | 19.15 Mn |
| Mar 31, 2022 | 18.88 Mn |
| Dec 31, 2021 | 19.41 Mn |
| Sep 30, 2021 | 19.37 Mn |
| Jun 30, 2021 | 5.30 Mn |